APA (7th ed.) Citation

Li, Y., Sun, W., Liu, H., & Ruan, X. Z. Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A. KeAi Communications Co., Ltd.

Chicago Style (17th ed.) Citation

Li, Yun, Wencong Sun, Hong Liu, and Xiong Z. Ruan. Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Alleviates Metabolic Dysfunction-associated Steatotic Liver Disease by Reducing the Expression of CD36 and OBP2A. KeAi Communications Co., Ltd.

MLA (9th ed.) Citation

Li, Yun, et al. Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Alleviates Metabolic Dysfunction-associated Steatotic Liver Disease by Reducing the Expression of CD36 and OBP2A. KeAi Communications Co., Ltd.